Clinical Trial

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed by placebo as adjuvant treatment.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2020-05-05; most recent amendment 2026-03-17.
Status change: Recruiting → Active, Not Recruiting 2022-09-06
Status change: Not Yet Recruiting → Recruiting 2020-06-08
Trial Details
NCT Number NCT04379635
Lead Sponsor BeiGene
Conditions Non Small Cell Lung Cancer
Enrollment 453 participants
Start Date 2020-05-29
Primary Completion 2023-08-21 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-18